In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Whether your family is affected by Alzheimer's or you simply want to learn more about the disease, this conference in Boca ...

For decades, scientists have targeted the sticky protein clumps that amass in Alzheimer's brains as a potential way of ...

The long-awaited Canadian approval of lecanemab has shifted physicians’ approach to Alzheimer’s disease, addressing previous ...

Investors take the value of the company's shares back to where they stood in July 2021 following Novo Nordisk's announcement.

Semaglutide does influence processes linked to Alzheimer’s, but these trials suggest it does not slow symptoms once they ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Alzheimer’s disease impacts tens of millions of families throughout the world, and projections state that more than 100 million people will be affected by the year 2050. The impact is not merely a ...

Alzheimer’s disease steals memory, independence and, too often, life itself. Drugs can ease symptoms, but none halt the march ...

AN ‘invisible fat’ hidden deep within the body can age the brain and raise the risk of Alzheimer’s, according to new research ...

Alzheimer's disease often begins many years before memory problems appear. During that silent phase, toxic changes slowly ...